NephroGenex, Inc. (NASDAQ: NRX) is an innovator in the development of drugs to treat kidney disease, with a first indication in diabetic nephropathy. NephroGenex has been pioneering the development of PYRIDORIN (pyridoxamine dihydrochloride), a late stage compound to treat diabetic patients with this slow-developing but potentially deadly disease. Pyridorin has the potential to slow or stabilize the progression to end-stage renal disease by inhibiting the formation of advanced glycation end products that have been implicated in the development of diabetic nephropathy. For more information, visit the company’s website at www.nephrogenex.com